Moreover, a recent study has demonstrated that S3I-201.1066, a novel small-molecule, binds with a high affinity to STAT3, disrupts STAT3 activation and function, and thereby increases anti-breast cancer activity in vitro and in vivo (Zhang et al., 2010; Yeh and Frank, 2016). This evidence concerns the gene STAT3 and breast carcinoma.